Christopher Hager

Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease

Gautier Hoarau, Pranab K. Mukherjee, Corinne Gower‐Rousseau et al. · mBio · 2016 · 474 citations · Full text

Life Sciences, Microbiology, Medical Microbiology +16

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

Emily L. Larkin, Christopher Hager, Jyotsna Chandra et al. · Antimicrobial Agents and Chemotherapy · 2017 · 393 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

Michael Graf, D. Ecker, R. Horowski et al. · Journal of Neural Transmission · 2004 · 191 citations

Life Sciences, Neurology, Neuroscience +13

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon et al. · Breast Cancer Research · 2021 · 154 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>In Vitro</i> and <i>In Vivo</i> Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

Christopher Hager, Emily L. Larkin, Lisa Long et al. · Antimicrobial Agents and Chemotherapy · 2018 · 140 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17